Treatment of patients with myelofibrosis and anemia

Myelofibrza je v porovnn s ostatnmi podjednotkami skupiny myeloproliferativnch onemocnn spojena s nejvy frekvenc doprovodnch konstitunch symptom a ptomnosti hepatosplenomegalie. K velmi astm pznakm myelofibrzy pat tak anmie rzn te, kter me bt pmm dsledkem patogenetickch mechanism myelofibrzy nebo nedoucm inkem samotn terapie JAK2 inhibitory. Oba typy anmi pinej nemocnm obdobn symptomy, nicmn pouze anmie spojen se samotnm zkladnm onemocnnm pedstavuje negativn prognostick faktor celkovho peit. Jednotliv JAK2 inhibitory se mezi sebou li svm vlivem na anmii.

Authors

Natália Podstávková

Publication Details

Journal: Onkologie
Published: 2025-10-08
DOI: https://doi.org/10.36290/xon.2025.041
Primary Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Treatment of patients with myelofibrosis and anemia

Natália Podstávková

Oct 8, 2025

Onkologie

Myeloproliferative Neoplasms: Diagnosis and Treatment

article

Treatment of patients with myelofibrosis and anemia

Natália Podstávková

October 8, 2025article en

Abstract

OnkologieVol. 19(4)

Openalex Percentile: Top 61%

Myeloproliferative Neoplasms: Diagnosis and Treatment

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Treatment of patients with myelofibrosis and anemia — Natália Podstávková · Onkologie (2025) | TGRS Research Map | TGRS